• Shaanxi Micot Pharmaceutical Technology reported XTL6001 research accepted for EASD 2026 oral sessions, signaling rising external visibility for the program.
• Additional XTL6001 analysis will be presented in Milan on Sep. 28–Oct. 2, 2026; initial data were already shown at ADA 2026.
• ASN Kidney Week 2026 in Denver on Oct. 21–25, 2026 will feature an XTL6001 poster focused on hyperuricemic nephropathy.
• Preclinical and Phase 1 findings presented to date support potential benefits in weight management, metabolic control, and renal protection.
• The asset has IND clearance in China and the U.S.; China Phase 1 has completed last patient last visit and database lock.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shaanxi Micot Pharmaceutical Technology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260817-12287115), on August 17, 2026, and is solely responsible for the information contained therein.